0001136261-20-000008.txt : 20200107
0001136261-20-000008.hdr.sgml : 20200107
20200107163014
ACCESSION NUMBER: 0001136261-20-000008
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200106
FILED AS OF DATE: 20200107
DATE AS OF CHANGE: 20200107
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mehra Raj
CENTRAL INDEX KEY: 0001757892
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22245
FILM NUMBER: 20513620
MAIL ADDRESS:
STREET 1: C/O SEELOS THERAPEUTICS, INC.
STREET 2: 300 PARK AVENUE, 12TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001017491
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 870449967
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 PARK AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10017
BUSINESS PHONE: (646) 998-6475
MAIL ADDRESS:
STREET 1: 300 PARK AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10017
FORMER COMPANY:
FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC.
DATE OF NAME CHANGE: 20100914
FORMER COMPANY:
FORMER CONFORMED NAME: NEXMED INC
DATE OF NAME CHANGE: 19970311
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2020-01-06
0
0001017491
SEELOS THERAPEUTICS, INC.
SEEL
0001757892
Mehra Raj
C/O SEELOS THERAPEUTICS, INC.
300 PARK AVENUE, 12TH FLOOR
NEW YORK
NY
10022
1
1
1
0
See Remarks
Stock Option (right to buy)
1.42
2020-01-06
4
A
0
731000
0
A
2030-01-06
Common Stock
731000
731000
D
1/4th of the shares subject to the option shall vest on January 6, 2021, and 1/4th of the shares subject to the option shall vest annually thereafter.
President, Chief Executive Officer, Chairman of the Board of Directors and Interim Chief Financial Officer
/s/ Raj Mehra, Ph.D.
2020-01-07